Citation Impact

62 standout
Sub-graph 1 of 18

Citing Papers

Different Targeting Ligands-Mediated Drug Delivery Systems for Tumor Therapy
2024 Standout
FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions
2024 Standout
2 intermediate papers

Works of Barbara Pro being referenced

Phase III trial of brentuximab vedotin and CHP versus CHOP in the frontline treatment of patients (pts) with CD30+ mature T-cell lymphomas (MTCL).
2015
Three-Year Survival Results From An Ongoing Phase 2 Study Of Brentuximab Vedotin In Patients With Relapsed Or Refractory Systemic Anaplastic Large Cell Lymphoma
2013

Author Peers

Author PFM Oncology Dermatology Neurology Last Decade Papers Cites
Barbara Pro 30 19 12 15 4 39
Monica Marton-Popovici 5 4 4 764
Lisette van Lieshout 127 2 20 936
P. S. Saneesh Babu 3 28 2 1 11 344
W. G�tze 14 817
M. Kuleva 2 1 16 424

All Works

Loading papers...

Rankless by CCL
2026